EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 216 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 Workout Wednesday – Back Stretches Part 1 July 22, 2020 Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... June 10, 2024 October is National Dental Hygiene Month October 1, 2020 Load more HOT NEWS Taking Control – Risks vs. Benefits Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung... Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and...
